Skip to content

AXIM BIOTECHNOLOGIES, INC.: 10-Q filed 2015-08-27

What AXIM BIOTECHNOLOGIES, INC. reported in its quarterly report filed 2015-08-27 (fiscal Q2 2015): 25 published measures, 72 facts as tagged in accession 0001387308-15-000136.

This filing

Form
10-Q (quarterly report)
Filed
2015-08-27
Fiscal period
fiscal Q2 2015
Accession
0001387308-15-000136 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All AXIM BIOTECHNOLOGIES, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2015-06-303,104,981USD
At 2014-12-31738,457USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2015-06-302,261,075USD
At 2014-12-311,319,180USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2015-06-30843,906USD
At 2014-12-31-580,723USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2015-06-3031,552USD
At 2014-12-31661,128USD
At 2014-06-304,838USD
At 2013-12-31127USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2015-04-01 to 2015-06-30-1,560,687USD91
2015-01-01 to 2015-06-30-2,067,633USD181
2014-04-01 to 2014-06-30-44,765USD91
2014-01-01 to 2014-06-30-52,386USD181

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2015-01-01 to 2015-06-30-629,576USD181
2014-01-01 to 2014-06-30-289USD181

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2015-04-01 to 2015-06-3012,112USD91
2015-01-01 to 2015-06-3012,112USD181
2014-04-01 to 2014-06-300USD91
2014-01-01 to 2014-06-300USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2015-01-01 to 2015-06-300USD181
2014-01-01 to 2014-06-305,000USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2015-06-30-2,759,597USD
At 2014-12-31-691,964USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2015-04-01 to 2015-06-300USD91
2015-01-01 to 2015-06-300USD181
2014-04-01 to 2014-06-300USD91
2014-01-01 to 2014-06-300USD181

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2015-01-01 to 2015-06-30509,000USD181
2014-01-01 to 2014-06-300USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2015-04-01 to 2015-06-30-1,560,499USD91
2015-01-01 to 2015-06-30-2,049,317USD181
2014-04-01 to 2014-06-30-162USD91
2014-01-01 to 2014-06-30-7,690USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2015-06-302,121,719USD
At 2014-12-31738,457USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2015-04-01 to 2015-06-30188USD91
2015-01-01 to 2015-06-3018,316USD181
2014-04-01 to 2014-06-300USD91
2014-01-01 to 2014-06-300USD181

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2015-06-301,861,075USD
At 2014-12-311,319,180USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2015-04-01 to 2015-06-301,572,611USD91
2015-01-01 to 2015-06-302,061,429USD181
2014-04-01 to 2014-06-30162USD91
2014-01-01 to 2014-06-307,690USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2015-04-01 to 2015-06-30251,025USD91
2015-01-01 to 2015-06-30373,927USD181
2014-04-01 to 2014-06-300USD91
2014-01-01 to 2014-06-300USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2015-06-3039,344,706shares
At 2014-12-3133,000,000shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2015-06-303,599,469USD
At 2014-12-31107,841USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2015-04-01 to 2015-06-30-1,560,687USD91
2015-01-01 to 2015-06-30-2,067,633USD181
2014-04-01 to 2014-06-30-162USD91
2014-01-01 to 2014-06-30-7,690USD181

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2015-01-01 to 2015-06-30-2,067,633USD181
2014-01-01 to 2014-06-30-52,386USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2015-04-01 to 2015-06-301,321,586USD91
2015-01-01 to 2015-06-301,687,502USD181
2014-04-01 to 2014-06-30162USD91
2014-01-01 to 2014-06-307,690USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2015-04-01 to 2015-06-30188USD91
2015-01-01 to 2015-06-3018,316USD181
2014-04-01 to 2014-06-300USD91
2014-01-01 to 2014-06-300USD181

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2015-01-01 to 2015-06-30651USD181
2014-01-01 to 2014-06-300USD181

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2015-01-01 to 2015-06-300USD181
2014-01-01 to 2014-06-305,000USD181

Inspect the source

Entity
AXIM BIOTECHNOLOGIES, INC. / CIK 0001514946
Captured
2026-09-20T09:13:30.666Z
SEC response SHA-256
5755093e2dfb1c20119737eacb251a5ef040e09cdc537c89d6edf9272249749e

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001514946.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))